

# WINTER 2026 SYMPOSIUM

## **Theranostics: Precision Imaging Meets Targeted Therapy**

Thursday, January 22, 2026  
8:00 AM - 12:20 PM PT - San Francisco, CA



## **Program Booklet**

**SPONSORED BY:**



*Advancing Research. Improving Lives.™*

***Theranostics: Precision Imaging Meets Targeted Therapy***
**January 22, 2026**
**San Francisco, CA**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<b><i>Planning Disclosures</i></b>				
Fabian, MD	Denise	<b>Planner/ Program Chair</b>	Mission Driven Tech	Consultant
Kohn, MD	Elise	<b>Planner/ Program Co-Chair</b>	Nothing to disclose	
Kunos, MD, PhD	Charles	<b>Planner/ Program Co-Chair</b>	Nothing to disclose	
Michalski, MD, MBA, FASTRO	Jeff	<b>Planner</b>	American Society of Therapeutic Radiation Oncology; Bayer	Leadership (American Society of Therapeutic Radiation Oncology) Consulting/Advisory Role (Bayer) Travel/Accommodations/Expenses (American Society of Therapeutic Radiation Oncology)
Soares, MD, PhD	Heloisa	<b>Speaker/ Moderator</b>	Ipsen; Sanofi; Exelixis; Novartis; Tersera; ITM	Honorarium
<b><i>Speaker Disclosures</i></b>				
Chauhan, MD	Aman	<b>Speaker</b>	Nothing to disclose	
Cheal, PhD	Sarah	<b>Speaker</b>	Nothing to disclose	
Fabian, MD	Denise	<b>Speaker/ Moderator</b>	Mission Driven Tech	Consultant
Flavell, MD, PhD	Robert	<b>Speaker</b>	Bristol Myers-Squibb	Research Grant
Hope, MD	Thomas	<b>Speaker</b>	Bayer; GE Healthcare, Lantheus; Sanofi; BMS; BlueEarth; Cardinal Health; Janssen; Telix	Consultant (Bayer; GE Healthcare, Lantheus; Sanofi; BMS; BlueEarth; Cardinal

**FACULTY DISCLOSURE INFORMATION**

			Pharmaceuticals; Novartis; Utter Therapeutics; AstraZeneca; Molecular Partners; AdvanCell; Curium	Health; Novartis; AstraZeneca; Molecular Partners; AdvanCell; Curium) Research Grant (GE Healthcare, Lantheus; Janssen; Telix Pharmaceuticals; Novartis) Equity Interest (Utter Therapeutics; AdvanCell; Curium)
Kunos, MD, PhD	Charles	<b>Speaker/ Moderator</b>	Nothing to disclose	
Malhotra, MD	Jyoti	<b>Speaker</b>	Fate Therapeutics; AstraZeneca; Bristol Meyers-Squibb; Daiichi Sankyo	DSMC Member (Fate Therapeutics) Consultant (AstraZeneca; Bristol Meyers-Squibb) Advisory Board Member (Daiichi Sankyo)
Michalski, MD, MBA, FASTRO	Jeff	<b>Speaker/ Moderator</b>	American Society of Therapeutic Radiation Oncology; Bayer	Leadership (American Society of Therapeutic Radiation Oncology) Consulting/Advisory Role (Bayer) Travel/Accommodations/Expenses (American Society of Therapeutic Radiation Oncology)
Ng, MD, PhD	Thomas	<b>Speaker/ Moderator</b>	Bayer; Lantheus	Research Funding (Bayer: research material support; Lantheus)
Soares, MD, PhD	Helosia	<b>Speaker/ Moderator</b>	Ipsen; Sanofi; Exelixis; Novartis; Tersera; ITM	Honorarium (Ipsen; Sanofi; Exelixis; Novartis; Tersera; ITM)
Tagawa, MD, MS, FACP, FASCO	Scott T.	<b>Speaker</b>	Johnson & Johnson; Sanofi; Astellas; Bayer; Eisai; Abbvie; Amgen; Pfizer; Novartis; Clarity; Genomic Health; POINT Biopharma; Blue Earth; Alkido Pharma; Gilead; Telix Pharma; Convergent Therapeutics; EMD Serono; Myovant; Merck; Daiichi Sankyo; Trans Thera; Regeneron; Ambrx; Boston Scientific (DSMB); General Electric; Lantheus; Abdera; Biohaven; Lilly; Genentech; Newlink; BMS; Inovio; AstraZeneca; Aveo; Rexahn; Atlab; Boehringer Ingelheim; Millenium; Bayer; Merck; Abbvie; Novartis; Ambrx; Clarity; AIQ; Janux; Alkido; Convergent	Consultant (Johnson & Johnson; Sanofi; Astellas; Bayer; Eisai; Abbvie; Amgen; Pfizer; Novartis; Clarity; Genomic Health; POINT Biopharma; Blue Earth; Alkido Pharma; Gilead; Telix Pharma; Convergent Therapeutics; EMD Serono; Myovant; Merck; Daiichi Sankyo; Trans Thera; Regeneron; Ambrx; Boston Scientific (DSMB); General Electric; Lantheus; Abdera; Biohaven; Lilly) Researcher (Sanofi; Astellas; Johnson & Johnson; Amgen; Lilly; Genentech; Newlink; BMS; Inovio; AstraZeneca; Aveo; Rexahn; Atlab; Boehringer Ingelheim; Millenium; Bayer; Merck; Abbvie; Novartis; Gilead; POINT Biopharma; Ambrx; Clarity; Telix; AIQ; Janux) Ownership (Alkido; Convergent)
Yap, PhD	Jeffrey	<b>Speaker</b>	Nexeos Bio; United Imaging Healthcare; Spectrum Dynamics; Lantheus; Radionetics Oncology; Blue Earth Diagnostics	Consultant (Nexeos Bio) Speaker (United Imaging Healthcare; Spectrum Dynamics) Clinical Trials (Lantheus; Radionetics Oncology; Blue Earth Diagnostics)
Engbert	Holley	<b>Staff</b>	Nothing to disclose	

**FACULTY DISCLOSURE INFORMATION**

Rush	Heather	<b>Staff</b>	Nothing to disclose	
Shumaker	Kara	<b>Reviewer/Staff</b>	Nothing to disclose	
Small, MPH	Michelle N	<b>Reviewer/Staff</b>	Nothing to disclose	
Alvarez Secord, MD	Angeles	<b>Reviewer/Edu-Chair</b>	AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis; Foundation Medicine; Gilead; Histosonics; Medtronic; Porject Nana; Up to Date; SGO; FWC; GOG Foundation; Amgen; Johnson & Johnson	Research funds to Institution (AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis) Honorarium (Merck; GSK) Advisory Board with Honoraria (AbbVie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; GSK; Genmab; Gilead; Histosonics; Medtronic; Merck) Medical Advisory Board (Porject Nana) Steering Committee Uncomp. (Oncoquest; Genmab) Royalties (Up to Date) Board of Directors (SGO; FWC; GOG Foundation) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	<b>Reviewer/Edu-Co-Chair</b>	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Blank, MD	Stephanie	<b>Reviewer</b>	AstraZeneca; Merck; Zentalis; Acrivon; Seattle Genetics; GSK	Research Funding to Institution
Mutch, MD	David	<b>Reviewer</b>	Nothing to disclose	
Zweizig, MD	Susan	<b>Reviewer</b>	Nothing to disclose	

# CONTINUING MEDICAL EDUCATION (CME)

## Accreditation Statement

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

## AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **4 AMA PRA Category 1 Credits™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement

The purpose of The GOG Foundation, Inc. CME program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

## Disclosure Declaration

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.


## Off-Label Statement

Some of the presentations and discussions in this session may include the off-label use of products/devices.



## How do I collect CME Certificates?

**Evaluation Link and QR code:**  
<https://s.pointerpro.com/wintersym26>



- **Scan QR code or click link** above to complete evaluation.
- **Click submit** and your certificate will automatically be emailed to you.

## CME Evaluations must be submitted by: **February 9, 2026**

If you have issues accessing your certificate or questions about CMEs, please contact: [cmeinfo@gog.org](mailto:cmeinfo@gog.org).

## Slide Presentations

A PDF version of all final slide presentations are available in the Symposium Session content on the Attendee Hub and the Meeting App

For questions or comments about this CME activity, please contact: Michelle N. Small, MHA  
Dir, Education Programs/CME Compliance  
at [msmall@gog.org](mailto:msmall@gog.org)

# Winter Symposium

## *Theranostics: Precision Imaging Meets Targeted Therapy*

JAN 22 2026 8 AM - 12:20 PM PT

San Francisco, CA

Program Chairs: Denise Fabian, MD

Program Co-Chairs: Charles Kunos, MD, PhD; Elise Kohn, MD

Planning Committee: Jeff Michalski, MD, MBA; Heloisa Soares, MD, PhD

**PROGRAM DESCRIPTION:** The NRG Winter 2026 Educational Symposium will provide a comprehensive look at theranostics and radiopharmaceutical therapy. The program will begin with an introduction to the scientific foundations of radiopharmaceuticals, outlining how these agents differ from external beam radiation, and the practical considerations of imaging, dosimetry, and safe delivery. Participants will also gain insight into the operational, regulatory, and infrastructural requirements needed to build a successful theranostics program within their institution.

Building on this foundation, the symposium will explore the evolving clinical applications of radiopharmaceutical therapy across multiple disease sites, highlighting the expanding evidence base and areas where these agents are already transforming patient care. The final session will spotlight emerging innovations, ongoing clinical trials, and novel agents that are pushing the field forward, including opportunities for collaborative research within NRG Oncology. The program will conclude with a forward-looking discussion on how radiopharmaceuticals are reshaping cancer care and how NRG is positioned to lead in advancing this transformative approach.

**TARGET AUDIENCE** This educational activity is directed towards members and non-members including our broad audience of physicians, research staff, new investigators, clinical research associates, basic researchers, medical physics, clinical trial nurses, patient advocates and other health care professionals interested in the treatment of cancer.

### LEARNING OBJECTIVES

Following this activity, participants will be better able to:

1. Develop a basic knowledge of the physics underlying radiopharmaceutical therapy
2. Explain the core radiobiological principles that guide radiopharmaceutical therapy
3. Define the applicability of theranostic agents
4. Identify the evidence supporting existing clinical and investigational use of theranostics
5. Be able to identify needed operational and programmatic elements for participation in a theranostics trial
6. Develop an awareness for what agents are currently available and what is forthcoming

### CONTINUING EDUCATION:

This symposium is approved to earn 4 AMA PRA Category 1 credits.

See presentation agenda on next page.

## Winter Symposium

**Theranostics: Precision Imaging Meets Targeted Therapy**

Thursday, January 22, 2026 - 8 am - 12:20 pm PT

Program Chairs: Denise Fabian, MD

Program Co-Chairs: Charles Kunos, MD, PhD; Elise Kohn, MD

Planning Committee: Jeff Michalski, MD, MBA; Heloisa Soares, MD, PhD

**Presentation Agenda**

Time	Topic/Title	Speaker/Moderator
6:30 am – 8:00 am	Breakfast Buffet	
8:00 am	Welcome/Opening Remarks	Charles A Kunos, MD/PhD
8:05 am	<b>Session 1: Background and Explanation</b>	<b>Moderator: Charles A Kunos, MD/PhD</b>
8:05 – 8:25 am	What is a Radiopharmaceutical?	Charles A Kunos, MD/PhD
8:25 – 8:45 am	Current Applicability of <u>Theranostics</u> Agents	Thomas Hope, MD
8:45 – 9:05 am	How to Use Radiopharmaceutical Therapy (RPT)	Thomas Ng, MD/PhD
9:05 – 9:25 am	How to Prepare Your Center for the Wave	Jeffrey Yap, PhD
9:25 - 9:30 am	Panel Discussion with Q/A	ALL
9:30 am	<b>Session 2: Evolution of Current Radiopharmaceutical Therapy and Clinical Applications</b>	<b>Moderator: Heloisa Soares, MD/PhD and Jeff Michalski, MD/MBA/FASTRO</b>
9:30 – 9:50 am	Evolution of RPT in GU Oncology	Jeff Michalski, MD/MBA/FASTRO
9:50 – 10:10 am	Evolution of RPT in Neuroendocrine Tumors	Heloisa Soares, MD/PhD
10:10 – 10:30 am	Evolution of RPT in Bone Metastases	Jyoti Malhotra, MD
10:30 – 10:35 am	Panel Discussion with Q/A	ALL
10:35 – 10:45 am	Break	
10:45 am	<b>Session 3: Ongoing Trials and Novel Concepts for <u>Theranostics</u> and RPT</b>	<b>Moderator: Denise Fabian, MD; Thomas Ng, MD/PhD</b>
10:45 – 11:00 am	Pre-Clinical Innovations in RPT	Robert Flavell, MD/PhD
11:00 – 11:15 am	<u>Pretargeted</u> Radioimmunotherapy	Sarah Cheal, PhD
11:15 – 11:30 am	Translating <sup>225</sup> Ac-J591 in Metastatic Prostate Cancer	Scott T. Tagawa, MD/MS/FACP/FASCO
11:30 – 11:45 am	<u>Triapine</u> M3814 in Neuroendocrine Tumors	Aman Chauhan, MD
11:45 – 12:00 pm	<u>[203/212Pb]Pb</u> -PSV-359 in Cervical Cancer	Denise Fabian, MD
12:00 – 12:15 pm	Panel discussion with Q/A	ALL
12:15 – 12:20 pm	Closing Remarks	Denise Fabian, MD



**Denise Fabian, MD**

Associate Professor

Residency Program Director of Radiation Oncology

Director of Gynecologic Radiation Oncology and Brachytherapy

University of Kentucky (UK)

Denise Fabian, MD is Associate Professor and Residency Program Director of Radiation Oncology at the University of Kentucky (UK). She also serves as the Director of Gynecologic Radiation Oncology and Brachytherapy, where she leads a specialized team that treats complex gynecologic malignancies. Under her leadership, UK has developed one of the most active and advanced brachytherapy programs in the country, providing comprehensive care for patients with cervical and endometrial cancers.

In addition to her clinical responsibilities, Dr. Fabian is active in theranostics research. She is principal investigator on several Phase I and Phase II clinical trials investigating radiopharmaceutical therapies and novel radiation modalities. Her recent work emphasizes improving outcomes in uterine cervix and endometrial cancer—especially within Kentucky—through the application of cutting-edge radiopharmaceutical and targeted radiation strategies.

Dr. Fabian holds a BA in Biochemistry & Molecular Biology (with a minor in International Relations) from Boston University and earned her MD at The Ohio State University College of Medicine (OSU), followed by residency training in Radiation Oncology at OSU.

She is a committed educator and mentor, with deep involvement in institutional and national committees. Dr. Fabian is a member of the American Brachytherapy Society (ABS), the American Society for Radiation Oncology (ASTRO), and serves on NRG Oncology's Cervix/Vulvar and Radiation Oncology General subcommittees. She is also affiliated with the Association for Directors of Radiation Oncology Programs (ADROP).

# PROGRAM CO-CHAIRS



## **Elise C. Kohn, MD F-AAAS F-ASCO**

CAPT (retired), United States Public Health Service  
Head, Gynecologic Cancer Therapeutics  
Head, Gastrointestinal Neuroendocrine Cancer Therapeutics  
Lead, NCI National Clinical Trials Network Core Correlative Science Cmte  
Clinical Investigations Branch, Cancer Therapy Evaluation Program  
Member, Women's Malignancy Branch, Center for Cancer Research  
National Cancer Institute

Elise Kohn's focus is to review, coordinate, and oversee development and execution of scientifically driven and practice-changing phase II-III clinical trials in gynecologic cancers and gastrointestinal neuroendocrine cancers. She provides disease and translational science expertise for drug development and clinical trials planning. Dr. Kohn also applies her expertise to the oversight and guidance of the NCTN Core Correlative Science Committee, which reviews proposals for correlative science projects using annotated clinical trial biospecimens. She continues to see and supervise targeted therapy clinical trial gynecologic cancer patients in the Women's Cancers Clinic that she initiated over twenty years ago.

Dr. Kohn spent over 2 decades overseeing a laboratory and clinical program in the National Cancer Institute intramural program focused on signal transduction molecular targets in invasion, metastasis, and angiogenesis, and proteomic applications, applied towards ovarian cancers. Her clinical program focused on application of novel agents and translational opportunities to women's cancers, especially ovarian cancer, via phase 1 and 2 studies. Dr. Kohn has served on numerous SGO and ASCO Committees, and a tour as member and Chair of the integration panel of the Department of Defense Ovarian Cancer Research Program. Her passion is mentoring, which she continues in a broad international forum since leaving the laboratory intramural setting. Dr. Kohn has received the Ovarian Cancer National Alliance's Rosalind Franklin Excellence in Ovarian Cancer Research Award, NIH Director's Merit Awards, and Diversity and Mentoring Awards. Dr. Kohn is a Fellow of the American Association for the Advancement of Science and the American Society of Clinical Oncology.



## **Charles Kunos, MD**

Case Western Reserve University  
Medical Officer in the Investigational Drug Branch of NCI CTEP  
Co-Founder of the Radiopharmaceutical Development Initiative

Charles Kunos, MD is a distinguished radiation oncologist and clinical trialist, currently serving as an adjunct full professor at the University of Kentucky with a focus on translational research and investigational therapeutics. He earned both his medical degree and doctorate from Case Western Reserve University, where he cultivated a deep expertise in oncologic sciences and radiopharmaceutical development.

## ***Charles Kunos - Bio Continued***

He previously held professorships at multiple NRG Oncology institutions and was instrumental in the implementation of the latest phase III uterine cervix cancer clinical trial. He had a pivotal role as a Medical Officer in the Investigational Drug Branch of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). During his tenure, he co-founded the Radiopharmaceutical Development Initiative, a groundbreaking effort to advance the clinical study of radioactive agents within the NCI portfolio. His leadership helped shape national strategies for integrating radiopharmaceuticals into early phase cancer trials.

## **MODERATORS / SPEAKERS**



### **Aman Chauhan, MD**

Associate Professor of Medical Oncology  
Leader of Neuroendocrine Tumor Program  
Co-Director of Theranostics Program  
University of Miami  
Sylvester Comprehensive Cancer Center  
Chair of NANETS Communications Committee  
Co-Chair SWOG NET Committee

Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects.

His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr. Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr. Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee.

Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society.



**Sarah Cheal, MD**

Assistant Professor of Biological Chemistry in Radiology  
Molecular Imaging Innovations Institute  
Weill Cornell Medicine  
Department of Radiology

Sarah Cheal, MD is an Assistant Professor of Biological Chemistry in Radiology at Weill Cornell Medicine (WCM). Before moving to WCM in January 2022, she was a member of the Nuclear Medicine research lab of Dr. Steven Larson at Memorial Sloan Kettering Cancer Center. Dr Cheal's research focuses on the development of a theranostic platform approach for bispecific antibody-based pretargeted radioimmunotherapy (PRIT) of solid human tumors. We call this strategy "DOTA-PRIT," which is short for "DOTA ligand bound radionuclide-based pretargeted radioimmunotherapy."



**Robert Flavell, MD, PhD**

Associate Professor in Residence  
Division Chief, Molecular Imaging and Therapeutics  
Departments of Radiology and Biomedical Imaging and Pharmaceutical Chemistry  
University of California, San Francisco

Robert Flavell, MD, PhD, is an Associate Professor and Division Chief of the Section of Molecular Imaging in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Flavell's laboratory focuses on the development of new molecular imaging and therapeutic tools for better understanding of disease progression in patients with prostate and other cancers. An area of major focus is the development of novel theranostic agents, where new therapies are paired with imaging agents against the same target. Dr. Flavell's research spans from basic chemistry and chemical biology projects, to translational and clinical studies.



**Thomas Hope, MD**

Vice Chair of Clinical Operations; Department of Radiology  
Director of Molecular Therapy  
Chief of Nuclear Medicine  
San Francisco VA Medical Center  
Chair of the Cancer Center's Molecular Imaging & Radionuclide Therapy  
Site Committee

Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center's Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008–2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013. Dr. Hope's main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.



**Jyoti Malhotra, MD**

Associate Professor, Medical Oncology & Therapeutics Research  
City of Hope Comprehensive Cancer Center

Jyoti Malhotra, MD is an Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. She is a thoracic medical oncologist, co-leader of the thoracic disease team and interim division chief. Dr Malhotra's expertise is in drug development and early phase therapeutics, and she has led multiple investigator-initiated clinical trials. She is also an active member of the SWOG cooperative group and serves on the NCCN panel for small cell lung cancer, SWOG metastatic subcommittee and IASLC Global Multidisciplinary Practice Standards committee.



**Jeff Michalski, MD, MBA**

Vice Chair of the Department of Radiation Oncology at Washington University Medical School  
Medical Director of the Siteman Cancer Center's Clinical Trial Office  
Principal Investigator for the Radiation Therapy Oncology Group at Washington University Medical School

Jeff Michalski, MD, MBA is a prostate cancer specialist, Chair of the Theranostics sub-Committee for NRG, and the Vice Chair of the Department of Radiation Oncology at Washington University Medical School. He serves as the medical director of the Siteman Cancer Center's Clinical Trial Office and has served as the Principal Investigator for the Radiation Therapy Oncology Group at Washington University. He earned his medical degree from the Medical College of Wisconsin in Milwaukee and completed his internship in internal medicine at Columbia-Presbyterian Medical Center in New York, and residency in radiation oncology at Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis.

Michalski's research interests include radiation dose escalation in the management of prostate cancer; precision radiation therapy to reduce toxicity in late neuro-cognitive effects in children with medulloblastoma; and assessment of quality of life in survivors of adult and childhood malignancies. He served as the Principal Investigator of the Advanced Technology Consortium (ATC) and coordinated Quality Assurance of radiation therapy trials in the cooperative group programs. As the leader of the RTOG ATIC, he established guidelines for participation of emerging technologies such as Intensity Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT) and Proton Beam Radiation Therapy (PBRT). He was instrumental in coordinating trials that involved advanced imaging, such as RTOG 0522 in head and neck cancer and stereotactic body radiation therapy in lung cancer, such as RTOG 0236. As the PI of the ATC, he coordinated quality assurance of clinical trials using PBRT for Massachusetts General Hospital, and MD Anderson Cancer Center. He served as Co-Principal Investigator on a joint contract with the Veteran's Administration Medical Centers and ASTRO to develop a system to provide continuous feedback on the progress, quality and safety of veterans' cancer therapy.



**Thomas Ng, MD, PhD**

Division of Nuclear Medicine & Molecular Imaging, Center for Systems Biology, Department of Radiology, Massachusetts General Brigham, Harvard Medical School

Thomas Ng, MD, PhD is an Assistant Professor of Radiology at Harvard Medical School. He is a physician/scientist within the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology at Mass General Brigham, and the Center of Systems Biology at Massachusetts General Hospital. He leads federally-funded translational and laboratory-based research programs focused on radiopharmaceutical therapies and serves as Associate Director of Radiopharmaceutical Therapy at MGH. He also serves as the Vice Chair on the Theranostics Subcommittee at NRG Oncology.



**Heloisa Soares, MD, PhD**

Medical Director, Clinical Trials Office  
Co-Physician Leader, Theranostics/GI Clinical Trials Research Groups  
Leader, University of Utah NET Destination Care program  
Associate Professor Division of Oncology  
Huntsman Cancer Institute

Heloisa Soares, MD, PhD is an Associate Professor of Medicine at the University of Utah's Huntsman Cancer Institute (HCI), where she leads the NET Destination Care Program, co-leads the GI Clinical Trials Research Group, and is the medical director for the Clinical Trials Office and Theranostics at HCI. A medical oncologist specializing in neuroendocrine cancers, she is a member of the NCCN Neuroendocrine & Adrenal Tumors Panel and serves as co-chair of the NCI NET Taskforce.



**Scott T. Tagawa, MD, MS**

Professor of Medicine and Professor of Medicine in Urology

Weill Cornell Medicine

Attending Physician, New York-Presbyterian - Weill Cornell Medical Center

Scott T. Tagawa, MD, MS, FASCO, FACP is a Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian - Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. Following Internship and Residency training there, he became Chief Resident and subsequently completed fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program, Director of Genitourinary Oncology for the Division of Hematology and Oncology, and Director of Medical Oncology for the Deane Prostate Health and Research Center.

He was recruited to Weill Cornell Medical College in 2007. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development in GU malignancies with a particular interest cell-surface targeting, including prostate-specific membrane antigen (PSMA) theranostics. Dr. Tagawa serves as Leader of the GU Disease Management Team of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He has served on multiple committees for the American Society of Clinical Oncology (currently the GU Guideline Advisory Group) and has been awarded Fellowship in ASCO. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies and has been named on multiple "top doctor" award lists.



**Jeffrey Yap, PhD**

Research Professor of Radiology and Imaging Sciences  
University of Utah

Jeffrey Yap, PhD received his PhD in medical physics from the University of Chicago. He is a research professor of radiology and imaging sciences at the University of Utah. Dr. Yap is also the director of the Center for Quantitative Cancer Imaging and Theranostics and a member of the Experimental Therapeutics Program at the Huntsman Cancer Institute. His research interests are in the development of quantitative imaging biomarkers, radiopharmaceuticals, and cancer therapeutics.

# Commercial Support



The NRG Oncology Foundation and The GOG Foundation would like to thank and acknowledge the following company for providing Independent Medical Education (IME) grant support associated with the 2026 NRG GOG Joint Educational Symposium titled:

***Theranostics: Precision Imaging Meets  
Targeted Therapy***

# Telix

